На этой странице перечислены больницы направления «Кардиоторакальная и сосудистая хирургия» (включая Heart Valve Repair) в Мумбаи, Индия, включая Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai и другие.
Спросите нас о «Heart Valve Repair» в Мумбаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 17 аккредитованных больниц (Кардиоторакальная и сосудистая хирургия) в Мумбаи, Индия
Рекомендуем🇮🇳 Nanavati Super Specialty Hospital
Больница занимает 1-е место в этом списке по указанному рейтингу (5/5, 12 отзывов).
🇮🇳 Kokilaben Dhirubhai Ambani Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.8/5, 1800 отзывов).
🇮🇳 Tata Memorial Hospital
Больница занимает 3-е место в этом списке по указанному рейтингу (4.8/5, 2500 отзывов).
🇮🇳 Apollo Hospitals, Navi Mumbai
Больница занимает 4-е место в этом списке по указанному рейтингу (4.8/5, 512 отзывов).
🇮🇳 Gleneagles Hospital, Mumbai
Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 615 отзывов).
🇮🇳 Lilavati Hospital And Research Centre
Больница занимает 6-е место в этом списке по указанному рейтингу (4.8/5, 724 отзывов).
🇮🇳 Jaslok Hospital
Больница занимает 7-е место в этом списке по указанному рейтингу (4.6/5, 129 отзывов).
🇮🇳 Gleneagles Global Hospitals (Global Hospitals)
Больница занимает 8-е место в этом списке по указанному рейтингу (4.6/5, 183 отзывов).
🇮🇳 Medicover Hospital, Navi Mumbai
Больница занимает 9-е место в этом списке по указанному рейтингу (4.6/5, 143 отзывов).
🇮🇳 KIMS Hospitals, Thane
Больница занимает 10-е место в этом списке по указанному рейтингу (4.6/5, 58 отзывов).
🇮🇳 Fortis Hospital, Mulund
Больница занимает 11-е место в этом списке по указанному рейтингу (4.5/5, 79 отзывов).
🇮🇳 Fortis Hiranandani Hospital, Vashi
Больница занимает 12-е место в этом списке по указанному рейтингу (4.5/5, 83 отзывов).
🇮🇳 Wockhardt Hospital
Больница занимает 13-е место в этом списке по указанному рейтингу (4.4/5, 30 отзывов).
🇮🇳 Wockhardt Super Speciality Hospital
Больница занимает 14-е место в этом списке по указанному рейтингу (4.4/5, 48 отзывов).
🇮🇳 S. L. Raheja Hospital
Больница занимает 15-е место в этом списке по указанному рейтингу (4.4/5, 121 отзывов).
🇮🇳 Saifee Hospital
Больница занимает 16-е место в этом списке по указанному рейтингу (4.3/5, 97 отзывов).
🇮🇳 Dr. L H Hiranandani Hospital
Больница занимает 17-е место в этом списке по указанному рейтингу (4.3/5, 141 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Кардиоторакальная и сосудистая хирургия» указано среди её специализаций и она находится в Мумбаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «heart valve repair» в Мумбаи, Индия?
Выбор подходящей больницы для «heart valve repair» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Кардиоторакальная и сосудистая хирургия», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Heart Valve Repair»
Heart valve repair surgery is a specialized cardiac procedure designed to restore the structural and functional integrity of damaged or diseased heart valves—most commonly the mitral, aortic, tricuspid, or pulmonary valves—without replacing them, thereby preserving the patient's native cardiac architecture and offering superior long-term outcomes. Contemporary valve repair techniques, including annuloplasty ring implantation, leaflet resection, chordal reconstruction, and transcatheter edge-to-edge repair (TEER), achieve procedural success rates exceeding 95% in high-volume centers, with 10-year freedom from reoperation rates above 85% for mitral valve repair. GAF Healthcare connects international patients with JCI- and NABH-accredited cardiac centers in India and JCI- and DHA-accredited facilities in the UAE, offering world-class surgical expertise, significantly reduced costs compared to Western benchmarks, and end-to-end patient coordination from first consultation through post-operative recovery. Hospital Stay: 7–12 days (including 2–3 days in cardiac ICU post-surgery) • Total Stay in Country (Fit-to-Fly): 4–6 weeks (international long-haul flight clearance typically granted at 4–6 weeks post-surgery following cardiologist sign-off and absence of complications such as atrial fibrillation, pericardial effusion, or wound issues) • Success Rate: 95–98% procedural success rate; 85–90% freedom from reoperation at 10 years for mitral valve repair in experienced centers
Clinical Overview
Heart valve disease affects an estimated 5 million people annually worldwide and encompasses a spectrum of pathologies including mitral valve prolapse, degenerative mitral regurgitation (Barlow's disease and fibroelastic deficiency), rheumatic mitral stenosis, bicuspid aortic valve disease, functional tricuspid regurgitation secondary to left-sided heart failure, and infective endocarditis sequelae. When a valve fails to open adequately (stenosis) or close competently (regurgitation/insufficiency), the resultant hemodynamic burden—pressure overload in stenosis, volume overload in regurgitation—progressively impairs myocardial contractility, induces ventricular remodeling, and culminates in symptomatic heart failure, atrial fibrillation, pulmonary hypertension, and increased mortality. Risk stratification prior to intervention employs validated scoring systems including the Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) score and the EuroSCORE II, alongside comprehensive echocardiographic grading using the American Society of Echocardiography (ASE) and European Association of Cardiovascular Imaging (EACVI) guidelines. The physiological rationale for repair over replacement is well established in current guidelines. The American College of Cardiology (ACC) and American Heart Association (AHA) 2021 Valvular Heart Disease Guidelines assign a Class I recommendation (Level of Evidence: B) to mitral valve repair over replacement for degenerative mitral regurgitation when durable repair is feasible at a comprehensive valve center, citing superior preservation of left ventricular geometry, elimination of prosthesis-related thromboembolic risk, avoidance of lifelong anticoagulation (with mechanical valves), and better long-term survival. Repair also maintains the native subvalvular apparatus—the chordae tendineae and papillary muscles—which is critical for preserving left ventricular systolic function post-operatively. The global standard of care for heart valve repair is performed at dedicated heart valve centers with a structured multidisciplinary Heart Team comprising interventional cardiologists, cardiac surgeons, cardiac anesthesiologists, imaging specialists (echocardiographers), and cardiac rehabilitation experts. Decision-making integrates clinical symptoms (NYHA functional class), echocardiographic severity grading (vena contracta width, effective regurgitant orifice area, proximal isovelocity surface area—PISA method, pressure half-time for stenosis), cardiac MRI volumetric quantification, cardiac CT for annular sizing, and coronary angiography to assess concomitant coronary artery disease requiring bypass grafting. India and the UAE have established internationally recognized Heart Team programs within their premier accredited institutions, delivering outcomes consistent with European and North American registry benchmarks.
Who is a Candidate?
• ELIGIBLE CANDIDATES: • Patients with severe symptomatic degenerative mitral regurgitation (Stage D) due to posterior leaflet prolapse, anterior leaflet prolapse, bileaflet prolapse, or chordal rupture—the most surgically repairable etiology • Patients with severe asymptomatic mitral regurgitation (Stage C) with preserved LVEF (>60%) and LVESD <40mm when repair durability is highly probable (>95%) at a Heart Valve Center of Excellence • Patients with rheumatic mitral stenosis with favorable valve morphology (Wilkins score ≤8) who are candidates for open mitral commissurotomy or percutaneous mitral balloon commissurotomy (PMBC/Inoue technique) • Patients with functional or secondary mitral regurgitation in the setting of heart failure (LVEF 20–50%) being considered for transcatheter edge-to-edge repair (TEER) using the MitraClip or PASCAL device when anatomically suitable (COAPT trial criteria: EROA ≥0.2 cm², optimized GDMT) • Patients with severe tricuspid regurgitation (annular dilation >40mm) undergoing concomitant left-sided valve surgery or isolated high-risk patients considered for transcatheter tricuspid interventions • Patients with non-calcific, pliable bicuspid aortic valve or isolated aortic regurgitation amenable to aortic valve repair (David reimplantation procedure, Yacoub remodeling procedure) • Symptomatic patients in NYHA Class II, III, or IV with valvular etiology confirmed by multimodality imaging • REQUIRED DIAGNOSTIC WORKUP: • Transthoracic Echocardiography (TTE): First-line assessment of valve morphology, severity grading, ventricular dimensions, LVEF, and pulmonary artery pressures • Transesophageal Echocardiography (TEE): Mandatory pre-operative and intraoperative tool; 3D TEE provides detailed leaflet segmental analysis (Carpentier classification: Type I, II, III), annular dimensions, and guides intraoperative repair assessment • Cardiac CT Angiography (CCTA): Annular sizing for transcatheter procedures, aortic root morphology, coronary anatomy, access planning • Cardiac MRI (CMR): Volumetric quantification of regurgitant fraction and LV remodeling when echocardiographic data is discordant • Coronary Angiography (invasive): Mandatory in all patients >40 years or with risk factors for CAD to identify concomitant coronary disease requiring CABG • Right Heart Catheterization: For patients with suspected pulmonary hypertension or discordant hemodynamic data • 6-Minute Walk Test (6MWT) and Cardiopulmonary Exercise Testing (CPET): Objective functional capacity assessment • Blood panel: CBC, CMP, coagulation profile (PT/INR, aPTT), HbA1c, lipid panel, thyroid function, BNP/NT-proBNP, blood group and crossmatch • Chest X-ray, ECG (12-lead), Holter monitoring if paroxysmal atrial fibrillation is suspected • CONTRAINDICATIONS / COMPLEX CONSIDERATIONS: • Heavily calcified, immobile, or severely dysplastic valve leaflets where repair is not durable (typically leads to valve replacement decision) • Active systemic infection or uncontrolled infective endocarditis with active sepsis (surgery delayed until clinical stabilization) • Severe irreversible LV dysfunction (LVEF <20%) with non-valvular etiology—may not benefit from isolated valve repair • Prohibitive surgical risk (STS PROM >15%) in patients who may be better served by transcatheter approaches or palliative management • Uncorrected coagulopathy or severe hepatic failure • Pregnancy (timing of intervention requires specialized multidisciplinary decision-making)
Treatment Options & Approaches
SURGICAL VALVE REPAIR TECHNIQUES (Open Heart Surgery via Cardiopulmonary Bypass): 1. MITRAL VALVE REPAIR (Gold Standard for Degenerative MR): • Posterior Leaflet Resection (Quadrangular or Triangular Resection): Carpentier's classic technique for P2 segment prolapse; the prolapsing segment is excised and the annulus is reapproximated with sliding annuloplasty to prevent systolic anterior motion (SAM). • Artificial Chordoplasty (Neo-chordal Replacement): Expanded PTFE (Gore-Tex) sutures are used to reconstruct ruptured or elongated chordae tendineae; the 'loop technique' and 'chordal transfer' are validated methods with high durability; preferred for anterior leaflet and bileaflet prolapse. • Annuloplasty Ring Implantation: A rigid, semi-rigid, or flexible annuloplasty ring (e.g., Carpentier-Edwards Physio II, St. Jude Medical Tailor ring, Medtronic Simulus) is sutured to the posterior annulus to remodel the dilated annulus and ensure repair durability; considered mandatory to accompany any leaflet repair to prevent recurrent annular dilation. • Alfieri Edge-to-Edge Stitch: A suture technique creating a double-orifice valve; now more commonly replicated transcatheterly via TEER devices. • Cleft Closure, Commissuroplasty: For specific congenital or rheumatic etiologies. 2. AORTIC VALVE REPAIR: • David Procedure (Valve-Sparing Root Replacement / Reimplantation): The aortic root is replaced with a Dacron graft while the native aortic valve is reimplanted within the graft, preserving the native cusps; preferred for Marfan syndrome, bicuspid aortopathy with cusp prolapse. • Yacoub Procedure (Remodeling): The three sinuses of Valsalva are replaced without annular stabilization; higher risk of annular re-dilation. • Cusp Repair Techniques: Plication, triangular resection, pericardial patch augmentation for isolated cusp prolapse or fenestration repair. 3. TRICUSPID VALVE REPAIR: • DeVega Annuloplasty: Purse-string suture technique for functional tricuspid regurgitation with annular dilation. • Ring Annuloplasty (Kay, MC3, Contour 3D rings): More durable than suture annuloplasty for significant tricuspid regurgitation. • Leaflet augmentation with autologous or bovine pericardium for rheumatic or post-endocarditis tricuspid disease. MINIMALLY INVASIVE SURGICAL APPROACHES: • Minimally Invasive Mitral Valve Surgery (MIMVS) via Right Mini-Thoracotomy (4–5 cm incision): Avoids full sternotomy; utilizes video-assisted or robotic-assisted visualization; equivalent repair rates to sternotomy with reduced blood loss, shorter ICU stay (1–2 days), faster return to activity (3–4 weeks vs. 6–8 weeks), and superior cosmesis; available at high-volume Indian and UAE centers. • Robotic-Assisted Mitral Valve Repair (da Vinci Robotic System): Fully endoscopic approach via 4–5 small port incisions (8mm); 3D magnified visualization; tremor filtration and articulated instruments allow precise leaflet and chordal work; outcomes equivalent to open surgery with the fastest recovery profile; offered at select tier-1 cardiac centers in both India and the UAE. • Port-Access Surgery: Femoral cannulation-based CPB with endoscopic visualization; intermediate between conventional MIMVS and full robotic. TRANSCATHETER (PERCUTANEOUS) APPROACHES (for High-Surgical-Risk Patients): • Transcatheter Edge-to-Edge Repair (TEER) — MitraClip (Abbott) / PASCAL (Edwards Lifesciences): Catheter-delivered clip(s) applied to the mitral valve leaflets via transseptal puncture under 3D TEE and fluoroscopic guidance; replicates the Alfieri stitch; FDA-approved for both degenerative MR (EVEREST II trial) and functional MR in HF patients (COAPT trial); ideal for patients with STS PROM >6% or anatomically eligible high-risk patients; performed under general anesthesia; hospital stay 2–3 days. • Percutaneous Mitral Balloon Commissurotomy (PMBC) / Inoue Balloon Technique: For rheumatic mitral stenosis with favorable morphology (Wilkins ≤8); catheter-based dilation of fused commissures via transseptal approach; avoids open surgery; excellent results in selected patients with restenosis-free survival >80% at 10 years in low-risk anatomy. • Transcatheter Tricuspid Interventions: Emerging technologies including TRILUMINATE (TriClip), FORMA spacer, CLASP TTr (Edwards); available at select centers. • TAVR (Transcatheter Aortic Valve Replacement): While primarily a replacement strategy for aortic stenosis, relevant context for patients with combined valvular disease or aortic repair failure. CONCOMITANT PROCEDURES FREQUENTLY PERFORMED: • Coronary Artery Bypass Grafting (CABG) combined with valve repair • Surgical Ablation for Atrial Fibrillation (Cox-Maze IV procedure using bipolar radiofrequency or cryoablation) — restores sinus rhythm in 70–90% of patients • Left Atrial Appendage Closure (LAAC) for stroke risk reduction in AF patients
Восстановление
PRE-OPERATIVE PHASE (Days –14 to –1): Step 1 — Remote Consultation & Case Review (2–4 weeks before travel): Patients share all diagnostic reports (echo reports, cardiac catheterization films, CT/MRI images, ECGs, blood results) with GAF Healthcare's medical coordination team. A senior cardiac surgeon at the selected facility reviews the case and issues a detailed treatment plan including recommended surgical approach (open vs. minimally invasive vs. transcatheter), estimated STS/EuroSCORE II risk, and cost estimate. A video consultation with the operating surgeon is arranged. Step 2 — Pre-Travel Optimization: Patients are counseled on pre-operative cardiac optimization: diuretic titration for volume overload, rate or rhythm control for atrial fibrillation, bridging anticoagulation protocols (for patients on warfarin), nutritional assessment, and anemia correction (target Hb >10 g/dL to reduce transfusion risk). Smoking cessation is mandatory ≥4 weeks prior. Step 3 — Arrival & Admission (Day –2 to –1): GAF Healthcare arranges airport pickup and transfer to pre-arranged accommodation or hospital guest house. Pre-operative workup is repeated or confirmed in-hospital: TEE, coronary angiography if not recently performed, blood group and crossmatch, anesthesia consultation, chest physiotherapy baseline assessment, consent process with surgical team. Nil-by-mouth instructions and pre-operative skin preparation are initiated. INTRAOPERATIVE PHASE (Day 0 — Surgery Day): Step 4 — Surgical Procedure (Duration: 3–6 hours for isolated valve repair; 5–8 hours for complex or combined procedures): Patient is placed under general anesthesia with continuous invasive hemodynamic monitoring (arterial line, central venous catheter, pulmonary artery catheter in complex cases). Intraoperative 3D Transesophageal Echocardiography (TEE) is performed by a dedicated cardiac anesthesiologist-echocardiographer to re-assess valve anatomy pre-repair and critically evaluate repair adequacy post-repair before separation from cardiopulmonary bypass (CPB). • For open surgery: Median sternotomy or right mini-thoracotomy incision; cardiopulmonary bypass initiated via aortic and venous cannulation; cold blood cardioplegia (antegrade ± retrograde) arrests the heart; surgeon performs the planned repair under direct visualization with loupe magnification or operating microscope. • For robotic surgery: Patient positioned with right side elevated; femoral arterial and venous cannulation for CPB; four robotic arms positioned through port incisions; da Vinci system provides surgeon with 3D endoscopic view at 10x magnification. • On-table TEE assessment post-repair: Confirms <1+ residual regurgitation, absence of systolic anterior motion (SAM), competent repair, and normal biventricular function before CPB is discontinued. • Defibrillation and cardiac de-airing; CPB weaned; protamine administered to reverse heparin; chest closed with sternal wires (open) or sutures (minimally invasive); chest drain(s) placed. POST-OPERATIVE PHASE — ICU (Days 1–3): Step 5 — Cardiac ICU (CICU) Recovery: Patient is transferred to CICU intubated; extubation typically within 4–8 hours post-operatively for uncomplicated cases (fast-track protocol). Continuous monitoring of cardiac rhythm, arterial blood pressure, central venous pressure, urine output, drainage. Vasopressor/inotrope weaning. Anticoagulation initiated: IV heparin followed by warfarin (target INR 2.0–3.0 for first 3 months post-repair, then aspirin alone if sinus rhythm maintained). Chest physiotherapy commenced from Day 1. Chest drain(s) removed Day 1–2. Epicardial pacing wires removed Day 3–5. POST-OPERATIVE PHASE — WARD (Days 3–7): Step 6 — Step-Down Ward & Mobilization: Patient transferred to cardiac step-down ward. Ambulation progressively increased: sitting Day 2–3, walking short distances Day 3–4, climbing stairs before discharge. Daily wound care; TTE performed on Day 4–5 to confirm repair integrity and rule out pericardial effusion. Oral medications consolidated: ACE inhibitor/ARB, beta-blocker, diuretic, anticoagulation. Cardiac rehabilitation education sessions initiated. Nutritional support optimized. Step 7 — Discharge Planning (Days 7–12): Discharge when: hemodynamically stable in sinus rhythm (or rate-controlled AF), wound healing confirmed, oral medications tolerability established, INR therapeutic if on warfarin, TTE confirming adequate repair. Discharge summary, medication list, INR monitoring schedule, and follow-up appointment (clinic review at 4–6 weeks) provided. POST-DISCHARGE RECOVERY (Weeks 2–6 in Country): Step 8 — Recovery Accommodation & Outpatient Follow-Up: GAF Healthcare arranges serviced apartment or hotel accommodation proximate to the hospital. Outpatient clinic review at Week 2: wound check, ECG, INR check (if on warfarin), TTE if indicated. Patients are advised: no driving for 6 weeks (sternotomy patients), no lifting >5 kg for 6–8 weeks, graduated walking program (target 30 minutes/day by Week 4). Sternal precautions maintained for 6–8 weeks (no push-pull activities). Step 9 — Fit-to-Fly Assessment (Week 4–6): Formal cardiologist clearance for long-haul flight issued when: sternal wound fully healed, no pericardial effusion, no active arrhythmia requiring in-hospital management, INR stable, patient ambulatory without limitation. Compression stockings and low-molecular-weight heparin (LMWH) are prescribed for the flight in selected high-risk patients (DVT prophylaxis). Emergency medical summary and contact details for home cardiologist provided. LONG-TERM RECOVERY MILESTONES: • Return to desk work: 6–8 weeks (open sternotomy); 3–4 weeks (minimally invasive/robotic) • Return to light physical activity/exercise: 8–12 weeks • Full physical recovery and return to unrestricted activity: 3–6 months • Annual surveillance TTE: Lifelong • Antibiotic prophylaxis for dental procedures: Recommended per AHA/ACC guidelines for repaired valves
Возможные риски
Heart valve repair surgery, while highly successful in experienced centers, carries a defined spectrum of procedural and post-operative risks that patients must understand and weigh against the natural history of untreated valve disease. Mortality risk for elective isolated mitral valve repair at high-volume centers is 0.5–1.5% (STS database benchmark); this rises to 3–8% for complex combined procedures (valve repair + CABG + AF ablation) or in patients with advanced heart failure (LVEF <35%). The primary procedure-specific risk is repair failure or residual significant regurgitation (>2+), identified intraoperatively on TEE, which may necessitate conversion to valve replacement during the same surgery (occurs in 5–10% of cases, higher with anterior leaflet pathology or rheumatic etiology). Early re-operation for repair failure within 30 days occurs in approximately 1–3% of cases. Cardiopulmonary bypass-related complications include systemic inflammatory response syndrome, acute kidney injury (4–8%; typically reversible), neurological events including stroke (1–3%; risk mitigated by intraoperative epiaortic ultrasound to identify aortic atheroma, CO2 field flooding, and meticulous de-airing), and transfusion-related complications. Cardiac rhythm disturbances are common post-operatively: new-onset atrial fibrillation occurs in 25–40% of patients in the first 72 hours (managed with rate control and anticoagulation; most convert to sinus rhythm within 6–8 weeks) and complete heart block requiring permanent pacemaker implantation occurs in <1% of mitral repairs (higher for aortic root procedures). Pericardial effusion, ranging from trivial to hemodynamically significant tamponade requiring drainage (1–2%), is detected by serial echocardiography. Wound complications include superficial or deep sternal wound infection (1–3%; higher in diabetic, obese, or COPD patients); minimally invasive and robotic approaches have significantly lower wound complication rates. Pneumonia and respiratory complications occur in 3–5%, particularly in smokers and those with baseline pulmonary disease; pre-operative physiotherapy and early post-operative mobilization mitigate this risk. Long-term risks include recurrent mitral regurgitation (freedom from reoperation 85–90% at 10 years for degenerative MR; lower for rheumatic, functional, or complex anterior leaflet pathology), endocarditis on the repaired valve (0.3–0.5% per year), and thromboembolic events during the anticoagulation transition period. Patients on post-operative anticoagulation (warfarin) face bleeding risks proportionate to INR lability. Transcatheter TEER procedures (MitraClip/PASCAL) carry lower procedural mortality (0.5–1%) but a higher rate of residual MR and potential need for repeat procedures compared to surgical repair.
Почему GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical support specifically designed to remove logistical barriers for international cardiac patients and their accompanying family members. VISA ASSISTANCE — INDIA: GAF Healthcare's dedicated visa coordination team assists patients in obtaining the India e-Medical Visa, which is available to citizens of 156 eligible countries and can be obtained within 72 hours of application. The e-Medical Visa permits a stay of up to 60 days with two permitted entries, and can be extended for up to 6 months if medically required (covering the post-operative recovery and fit-to-fly period). GAF Healthcare provides the mandatory hospital invitation letter from the treating institution, which is a required document for e-Medical Visa applications. Up to two companions (Attendant e-Visas) may accompany the patient under the same application category. VISA ASSISTANCE — UAE (DUBAI / ABU DHABI): Citizens of 49 countries receive visa-free access to the UAE for 30–90 days, covering the full treatment and recovery period for most heart valve repair patients. Citizens of most other countries are eligible for a UAE Visit Visa or Medical Treatment Visa obtainable on arrival or via advance application. GAF Healthcare coordinates with UAE hospital international patient departments to facilitate any required medical treatment visa documentation and extension letters for the post-operative recovery period. PRE-ARRIVAL COORDINATION: A dedicated GAF Healthcare Patient Relationship Manager (PRM) is assigned to each patient from the point of case registration. The PRM coordinates all hospital appointments, schedules surgeon consultations, and ensures a seamless admission process. A pre-travel checklist including documentation requirements, medication management instructions (particularly for anticoagulants and antiplatelet agents), and travel insurance recommendations is provided. AIRPORT TRANSFERS & GROUND TRANSPORTATION: GAF Healthcare arranges private, medically equipped vehicle transfers from the international airport to the hospital or recovery accommodation upon arrival, and for all subsequent inter-facility transfers (e.g., hospital to recovery apartment) and the final airport transfer at discharge. Vehicles are air-conditioned and drivers are briefed on passenger medical status. ACCOMMODATION FOR PATIENTS & ATTENDANTS: For the post-discharge recovery period (typically 2–4 weeks), GAF Healthcare arranges accommodation in vetted, comfortable serviced apartments or hotels within close proximity to the treating hospital. Accommodation options range from standard to premium and are selected based on patient preference and budget. Attendant accommodation during the hospital stay (ICU and ward phase) is facilitated through hospital guest rooms or proximate lodging. Housekeeping, laundry, and meal provisions are coordinated per patient preference. TRANSLATION & CULTURAL SUPPORT: Dedicated medical interpreters fluent in Arabic, Russian, French, Swahili, Uzbek, and other major languages are available for in-person interpretation during surgical consent discussions, ward rounds, and discharge counseling. All written discharge summaries, medication schedules, and follow-up instructions can be provided in the patient's preferred language. TELEMEDICINE FOLLOW-UP: Post-return home, GAF Healthcare facilitates virtual follow-up consultations between the patient and the treating cardiac team at 4 weeks, 3 months, and 6 months post-surgery, supported by digital transmission of local echocardiography and blood test results to the treating surgeon for remote review.
Частые вопросы о процедуре «Heart Valve Repair»
What is the cost of Heart Valve Repair Surgery in India vs. the UAE?
How long do I need to stay in the country before I am fit to fly home after Heart Valve Repair Surgery?
What is the success rate of Heart Valve Repair Surgery?
Как GAF Healthcare помогает выбрать лучшую больницу для «heart valve repair» в Мумбаи, Индия
Найдите лучшие больницы для «heart valve repair» в Мумбаи, Индия
На этой странице представлено 17 больниц в Мумбаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Heart Valve Repair» в Мумбаи, Индия
Сколько больниц направления «Кардиоторакальная и сосудистая хирургия» представлено в Мумбаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Мумбаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Heart Valve Repair» в Мумбаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.